Mesenchymal stem cells (MSCs) have been widely used in a number of applications designed to aid in the regeneration and healing of human tissue. Prized for their multipotent capacity to differentiate into a variety of other specific cell types, MSCs have consistently demonstrated the ability to seek out damaged tissue while also reducing inflammation and promoting…
Currently, it’s estimated that nearly 1.5 million Americans are living with type 1 diabetes (T1D), a number that is expected to increase to over 2 million by the year 2040[1]. In the U.S. alone, healthcare costs and lost wages directly related to T1D currently exceed $16 billion per year. While the most common treatment…
Mesenchymal stem cells (MSCs) have demonstrated the ability to differentiate into a number of different cells; they also demonstrate immunomodulatory properties that have great potential for use as a stem cell-based therapeutic treatment option and for the treatment of autoimmune diseases - including rheumatoid arthritis (RA). RA is a chronic and debilitating inflammatory disorder that…
The number of people experiencing autoimmune diseases (ADs) continues to increase worldwide. Currently, it's estimated that between 2 and 5% of the global population is afflicted with the most severe forms of these diseases, including type 1 diabetes (T1DM), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). An autoimmune disease can occur nearly anywhere in…
Spinal cord injury (SCI) continues to be a significant cause of disability. In fact, it is estimated that annual SCIs account for nearly 18,000 injuries in the United States and between 250,000 and 500,000 injuries worldwide[1]. While the main cause of SCIs in the United States continues to be motor vehicle accidents, other contributors include…
Stem cells, and specifically mesenchymal stem cells (MSCs), have long been considered as a promising therapeutic agent for the treatment of a wide variety of degenerative and ischemic diseases. Over this time, MSC immunomodulation, their capacity for multilineage differentiation, and their ability to self-renew have been well established and are now considered to be clinically…
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder that causes your immune system to mistakenly attack its own tissue and specifically affects the lining of the joints, resulting in painful swelling, bone erosion, and eventually permanent joint deformity. With an estimated 1.5 million people in the U.S. living with RA, the disease affects nearly…
Osteoarthritis (OA) is the most common form of arthritis, affecting over 525 million people around the world. Characterized by pain, swelling, and stiffness resulting from the degradation of cartilage that provides cushion and protection between our bones, OA is an inflammatory condition without a clear and effective treatment. OA most commonly affects the hands, knees,…
Human Mesenchymal Stem Cells (hMSCs) are the non-hematopoietic, multipotent stem cells with the capacity to differentiate into mesodermal lineages such as osteocytes, adipocytes, and chondrocytes as well ectodermal (neurocytes) and endodermal lineages (hepatocytes). Until recently, when the immunomodulation properties of MSCs were proven to be clinically relevant, the use of these stem cells was met…
Mesenchymal stem cells (MSCs) have been widely studied and increasingly recognized as a potential therapeutic with the ability to initiate and support tissue regeneration and remodeling. While over 1100 clinical trials have been conducted to assess the therapeutic benefits of MSCs, there continues to be widespread variation surrounding the potential treatment outcomes associated with these…
We have answers. Speak with a Stemedix Care Coordinator today with no obligation. Give us a call!